Advertisement
UK markets close in 2 hours 5 minutes

  • FTSE 100

    8,057.66
    +17.28 (+0.21%)
     

  • FTSE 250

    19,633.04
    -86.33 (-0.44%)
     

  • AIM

    753.70
    -0.99 (-0.13%)
     

  • GBP/EUR

    1.1665
    +0.0020 (+0.17%)
     

  • GBP/USD

    1.2473
    +0.0011 (+0.09%)
     

  • Bitcoin GBP

    50,519.05
    -2,494.23 (-4.70%)
     

  • CMC Crypto 200

    1,345.33
    -37.25 (-2.69%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.23
    -0.58 (-0.70%)
     

  • GOLD FUTURES

    2,331.50
    -6.90 (-0.30%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,884.82
    -203.88 (-1.13%)
     

  • CAC 40

    7,978.53
    -113.33 (-1.40%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

HEXO (HEXO) Dips More Than Broader Markets: What You Should Know

Zacks Equity Research

HEXO (HEXO) closed at $4.91 in the latest trading session, marking a -1.8% move from the prior day. This change lagged the S&P 500's daily loss of 0.62%. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, lost 0.74%.

Prior to today's trading, shares of the cannabis producer had lost 14.24% over the past month. This has lagged the Medical sector's loss of 1.47% and the S&P 500's gain of 2.8% in that time.

Investors will be hoping for strength from HEXO as it approaches its next earnings release.

It is also important to note the recent changes to analyst estimates for HEXO. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

ADVERTISEMENT

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.74% higher. HEXO is currently a Zacks Rank #3 (Hold).

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 82, putting it in the top 33% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
HEXO Corp. (HEXO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research